Physicians' Academy for Cardiovascular Education

RAASi and Hyperkalaemia in Cardio Renal Disease: Opportunities for optimizing outcomes

Meeting report with presentation slides and video of a PACE-CME symposium held during ERA-EDTA 2019 in Budapest, Hungary on RAASi and hyperkalaemia

Managing hyperkalemia in cardiorenal patients: novel therapeutic insights to optimize outcomes

10' education - Aug. 28, 2019 - Prof. Matthew Weir, MD
Prof. Weir addresses the need for management of hyperkalemia in CKD patients, discusses RAASi enabling and presents novel therapeutic considerations.

Prof. Weir addresses the need for management of hyperkalemia in CKD patients, discusses RAASi enabling and presents novel therapeutic considerations.

Addressing the risk of hyperkalemia in HF: is there a sweet spot for potassium binding?

10' education - Aug. 21, 2019 - Prof. van der Meer, MD, PhD
Prof. van der Meer uses a case description to explain the issue of RAASi uptitration in the presence of hyperkalemia in HF. Furthermore, he talks about outcomes and new treatment options in HF patients with hyperkalemia.

Prof. van der Meer uses a case description to explain the issue of RAASi uptitration in the presence of hyperkalemia in HF. Furthermore, he talks about outcomes and new treatment options in HF patients with hyperkalemia.

RAAS inhibition in patients with kidney disease: Balancing the benefits and risks

10' education - July 12, 2019 - ERA-EDTA 2019 - Prof. Patrick Rossignol, MD
Although RAAS inhibition reduces proteinuria and hypertension in cardio-renal patients, it is associated with increased risk of hyperkalemia. Prof. Rossignol shares data on the addition of patiromer in patients using spironolactone for the mangement of CKD with resistant hypertension.

Although RAAS inhibition reduces proteinuria and hypertension in cardio-renal patients, it is associated with increased risk of hyperkalemia. Prof. Rossignol shares data on the addition of patiromer in patients using spironolactone for the mangement of CKD with resistant hypertension.

Slides: Managing hyperkalaemia in cardiorenal patients: Novel therapeutic insights to optimize outcomes

Slides (presentation) - July 3, 2019 - Matthew Weir, MD – Baltimore, MD, USA - CME symposium held during ERA EDTA 2019
This lecture by prof. Matthew Weir was part of a CME-accredited symposium

Slides as educational service to PACE members and meeting participants

Slides: Addressing the risk of hyperkalaemia: Is there a sweet spot for potassium binding?

Slides (presentation) - July 3, 2019 - Peter van der Meer, MD – Groningen, the Netherlands - CME symposium held during ERA EDTA 2019
This lecture by prof. Peter van der Meer was part of a CME-accredited symposium

Slides as educational service to PACE members and meeting participants

Slides: RAAS inhibition in patients with kidney disease: Balancing the benefits and risks

Slides (presentation) - July 3, 2019 - Patrick Rossignol, MD – Nancy, France - CME symposium held during ERA EDTA 2019
This lecture by prof. Patrick Rossignol was part of a CME-accredited symposium

Slides as educational service to PACE members and meeting participants

RAASi and Hyperkalaemia in Cardio Renal Disease: Opportunities for optimizing outcomes
RAASi and Hyperkalaemia in Cardio Renal Disease: Opportunities for optimizing outcomes